Our previous studies demonstrated that the prostaglandin synthase, cyclooxygenase-2 (COX-2), could mediate the progress of prostatic hypertrophy in rats treated with BPA (10, 30, 90 μg/kg/day) [23], accompanying the overexpression of the epidermal growth factor receptor (EGFR) [24]. Here, PTGS2 is linked to benign prostatic hyperplasia.